Moffitt and Fulgent Pharma Collaborate on Personalized Cancer Treatments

Moffitt Cancer Center and Fulgent Pharma have entered into a strategic partnership aimed at advancing personalized cancer therapies. This collaboration seeks to combine Moffitt's clinical acumen with Fulgent's innovative nanotherapeutics and genomics platforms to speed up the development of specialized cancer treatments.

The partnership is structured to enhance both pre-clinical and clinical development phases of cancer therapeutics. One significant aspect of this agreement is that it allows Fulgent to have prioritized access to Moffitt's extensive clinical resources and expertise. This access is expected to hasten the clinical trial processes, improve patient screening protocols, and streamline data sharing between the entities. Such measures aim to bring investigational therapies to patients more quickly and efficiently.

A key highlight of Fulgent's contributions is their development of FID-007, a soluble form of the chemotherapy drug paclitaxel. Utilizing nanoencapsulation technology, FID-007 has shown promising results in early Phase I clinical trials, demonstrating significant tumour reduction in several cancer types, including breast, head and neck, lung, bile duct, and pancreatic cancers.

This partnership is also centered on the co-development of new, tailored cancer treatments. Moffitt will leverage its wide-ranging scientific expertise, access to tissue samples, and robust nonclinical research resources. On the other hand, Fulgent will contribute its cutting-edge nano-particle drug development platform along with advanced genetic and genomic testing capabilities.

Patrick Hwu, president and CEO of Moffitt, expressed optimism about the partnership, stating, “This partnership aligns with Moffitt’s mission to contribute to the prevention and cure of cancer. We are looking forward to working with Fulgent to accelerate the translation of scientific discoveries into lifesaving treatments for our patients.”

In addition to this collaboration, it is noteworthy that Fulgent Pharma was acquired by Fulgent Genetics for $100 million in November 2022, which further strengthens the financial and technological foundations of the partnership.

This strategic alliance aims to markedly improve the speed and efficiency with which new cancer therapies are developed and tested, making significant strides in personalized cancer treatment options. By pooling their resources and expertise, Moffitt Cancer Center and Fulgent Pharma are poised to make impactful advancements in the field of oncology, offering renewed hope to cancer patients through faster and more effective treatment options.